Shareholder Class Action

In a federal class action, shareholders say directors are selling Abaxis (medical devices) too cheaply through an unfair process to Zoetis, for $83 a share or $2 billion.

SAN FRANCISCO (CN) — In a federal class action, shareholders say directors are selling the medical-device company Abaxis too cheaply through an unfair process to Zoetis, for $83 a share or $2 billion.

Categories / Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.